TFF Pharmaceuticals amends bylaws to adopt universal proxy rules and other governance changes

TFF Pharmaceuticals, Inc.

Board approved First Amended and Restated Bylaws on March 31, 2023, effective immediately.
Section 2.14 adopts universal proxy provisions under Rule 14a-19 of the Exchange Act.
Section 2.12 permits stockholder action by majority written consent unless prohibited by charter.
Section 3.9 allows removal of directors with or without cause by majority vote of shares.
Other revisions reflect recent changes in Delaware General Corporation Law; no material impact on prior disclosures.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TFF Pharmaceuticals, Inc.: Adopted First Amended and Restated Bylaws with universal proxy provisions, majority written consent for stockholder action, and director removal provisions (effective 2023-03-31).

Change: bylaw amendment
Effective: 2023-03-31

Exact text from the filing

On March 31, 2023, our Board of Directors approved and adopted our First Amended and Restated Bylaws (“Amended Bylaws”) of the Corporation.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001213900-23-027969

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.